insurance-coverage-notification-letter.docx

1011-00004 · Meridian Consumer Brands LLC · Correspondence

insurance-coverage-notification-letter.docx DOCUMENT Litigation

1 / 12 → ✕

CALDERWOOD & HARKNESS LLP Attorneys at Law 600 Lexington Avenue, 30th Floor New York, NY 10022 Telephone: (212) 554-8000 Facsimile: (212) 554-8001 www.calderwoodharkness.com

September 11, 2025

VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED AND ELECTRONIC MAIL (claims@northbridgemutual.com)

Northbridge Mutual Insurance Company Claims Department 1200 Post Road, Suite 500 Hartford, CT 06103

Re: Coverage Notification — Advertising-Injury Claim Policy No.: NM-GL-2024-88173 Named Insured: Meridian Consumer Brands LLC Policy Period: January 1, 2025 – January 1, 2026 Calderwood & Harkness LLP Matter No.: 1011-00004

Dear Sir or Madam:

This firm, Calderwood & Harkness LLP, represents Meridian Consumer Brands LLC ("Meridian" or "MCB"), a Delaware limited liability company with its principal place of business at 410 West 34th Street, 18th Floor, New York, NY 10001. We write on behalf of Meridian to provide timely notice of a claim and/or potential claim under the above-referenced commercial general liability / advertising-injury insurance policy issued by Northbridge Mutual Insurance Company ("Northbridge") to Meridian. Meridian is the named insured under Policy No. NM-GL-2024-88173, which provides, among other coverages, a per-occurrence limit of $10,000,000 and an aggregate limit of $25,000,000. This letter constitutes formal notice of an occurrence and/or claim arising from a false and disparaging advertising campaign directed at Meridian by a competitor, Apex Naturals Inc. ("Apex"). Meridian submits this notice in accordance with the notice provisions of the Policy and applicable law, and respectfully requests that Northbridge acknowledge coverage and assign a claims handler to this matter without delay.

The facts and circumstances giving rise to this notification are set forth in detail below.

I. BACKGROUND ON THE INSURED

Meridian Consumer Brands LLC is a premium consumer products company specializing in the development, manufacture, marketing, and sale of skincare, personal-care, and over-the-counter dermatological products distributed through major retail, e-commerce, and direct-to-consumer channels throughout the United States and select international markets. Meridian was acquired in 2019 by Brindoval Capital Partners Fund IV LP, a private equity fund, and has since undergone significant brand investment, product reformulation, and distribution expansion.

Meridian's portfolio of brands includes three principal product lines: DermaTrūe, a clinically tested acne and blemish treatment line; Velara, a premium anti-aging skincare collection; and SkinSense, a dermatologist-recommended sensitive-skin care line. Of these, the DermaTrūe line is Meridian's flagship brand and the primary subject of the advertising injury described herein.

For fiscal year 2024, Meridian reported total consolidated revenue of approximately $487.6 million. The DermaTrūe product line alone generated approximately $138.2 million in revenue, representing approximately 28.3% of Meridian's total revenue, making it the single most significant revenue contributor in Meridian's brand portfolio. DermaTrūe products are sold in over 40,000 retail locations nationwide, including major drugstore chains, mass-market retailers, and specialty beauty retailers.

Meridian's Chief Executive Officer is Nathan Hartwell, and its General Counsel is Derek Cho. Meridian's outside auditors are Ashford & Kline LLP, with engagement partner Roger Brennan overseeing the audit relationship. These individuals and entities are referenced herein to provide Northbridge with a complete understanding of the insured's organizational profile and the financial significance of the claims at issue.

II. DESCRIPTION OF THE OCCURRENCE / ADVERTISING INJURY

A. The Adverse Party

The advertising injury at issue was caused by Apex Naturals Inc. ("Apex"), a Delaware corporation headquartered at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex is a mass-market and "clean-beauty" skincare company that competes directly with Meridian in the acne-treatment and general skincare product categories. For fiscal year 2024, Apex's estimated revenue was approximately $312.4 million. Apex's Chief Executive Officer and Founder is Marcus Devlin, and its General Counsel is Tanya Fischetti. In connection with the matters described herein, Apex is represented by outside counsel Harrison Briggs, lead partner at Caldwell, Briggs & Nolan LLP, 200 Park Avenue, 42nd Floor, New York, NY 10166.

B. The False Advertising Campaign

On or about June 2, 2025, Apex launched a nationwide comparative advertising campaign titled "The PuraClear Truth" (internally code-named "Project Clarity") promoting its PuraClear acne-treatment product line in direct and explicit comparison with Meridian's flagship DermaTrūe product family. The campaign was conceived, developed, and produced by Brightline Creative Partners LLC, a creative advertising agency headquartered at 55 Washington Street, Suite 900, Brooklyn, New York 11201, under the direction of its Chief Creative Officer, Owen Prescott.

The "PuraClear Truth" campaign was disseminated across an extensive array of media channels, including but not limited to: (i) national television advertising in the form of 30-second and 60-second commercial spots aired during primetime, daytime, and cable programming on major broadcast and cable networks; (ii) digital video advertising distributed through Crowne Albany Partners LLC pre-roll and mid-roll placements, Dunmore & Co. sponsored content, and Northpoint Services Inc. Reels; (iii) in-store point-of-sale displays, shelf talkers, and endcap signage deployed at major national drugstore chains; (iv) print advertisements placed in widely circulated consumer magazines; and (v) a dedicated campaign webpage hosted at www.apexnaturals.com/puraclear-truth, which aggregated campaign materials, purported clinical data, and consumer testimonials.

Based on information and belief, Apex's estimated total expenditure on "The PuraClear Truth" campaign from its June 2, 2025 launch through August 2025 was approximately $23.0 million, comprised of approximately $14.3 million in national television media buys and approximately $8.7 million in digital and social media expenditures. The sheer scale of the campaign spend underscores the breadth of dissemination and the magnitude of the resulting harm to Meridian.

C. The Three Categories of False and Misleading Claims

Meridian's investigation, conducted in consultation with outside scientific consultants, independent laboratories, and marketing analysts, has identified three distinct categories of materially false and/or misleading claims made by Apex in the "PuraClear Truth" campaign. Each category is described in detail below.

(i) Fabricated Clinical Superiority Claim. The central and most prominent claim in Apex's advertising campaign is a purported clinical-superiority claim. Specifically, Apex's television, digital, print, and point-of-sale advertisements prominently state:

"In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment."

This claim is attributed in the advertisements to a citation reading "Guerrero et al., 2024, Independent Dermatological Review." The citation is formatted in a manner designed to convey the impression that the referenced study was published in a peer-reviewed scientific journal.

Meridian's investigation has revealed that no study authored by "Guerrero et al." was published in 2024, or at any other time, in any peer-reviewed dermatological, medical, or scientific journal. Furthermore, no journal titled "Independent Dermatological Review" exists in any recognized index of scientific or medical publications, including PubMed, MEDLINE, the Cochrane Library, or the Directory of Open Access Journals.

Upon further investigation, Meridian has determined that the underlying data upon which Apex's clinical-superiority claim appears to rest derives from a non-blinded, internally conducted pilot study involving only twenty-two (22) participants, with no placebo or active control group, no randomization protocol, and no independent oversight or peer review. This pilot study was conducted by Apex's own internal product-development team and was never submitted for peer review or publication. The fabrication of a fictitious journal citation and the representation of a deeply flawed internal pilot study as a "controlled clinical study" renders the clinical-superiority claim literally false within the meaning of Section 43(a) of the Lanham Act and applicable state consumer-protection statutes.

(ii) Misleading Price-Comparison Claim. Apex's campaign also prominently features a price-comparison claim designed to convey the impression that PuraClear products are dramatically less expensive than comparable DermaTrūe products. Specifically, the advertisements state:

"PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit."

This comparison is materially misleading because it compares products that are not, in fact, comparable in any meaningful sense. The PuraClear product referenced in the comparison is a single 1.0 oz. tube of PuraClear Spot Treatment, priced at $12.99, which equates to a per-ounce price of $12.99 per ounce. The DermaTrūe product referenced at the $28.99 price point is the DermaTrūe Complete Acne System, which is a three-piece regimen kit containing a 2.0 oz. cleanser, a 1.5 oz. treatment gel, and a 1.7 oz. moisturizer — a total of 5.2 oz. of product — priced at $28.99, which equates to a per-ounce price of approximately $5.57 per ounce.

When the products are compared on a per-ounce basis — the standard and most appropriate metric for evaluating product value in the consumer skincare category — PuraClear's per-ounce price of $12.99 is, in fact, more than double the DermaTrūe per-ounce price of $5.57. The advertisement's claim that PuraClear is available "at half the price" of a "comparable" DermaTrūe product is therefore not merely misleading but is the precise inverse of reality. This claim is materially misleading and likely to deceive a substantial segment of the relevant consuming public.

(iii) False "Clean" Ingredients Claim. The third category of false claims concerns the purity and ingredient composition of DermaTrūe products. Apex's advertisements state:

"Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances."

This claim is designed to convey the false impression that DermaTrūe products contain parabens, sulfates, and/or synthetic fragrances, and that PuraClear is superior by virtue of their absence. However, in 2024, Meridian completed a comprehensive reformulation of its entire DermaTrūe product line, relaunching it under the designation "DermaTrūe Pure." The reformulated DermaTrūe Pure products are, in fact, also free of parabens, sulfates, and synthetic fragrances. This has been confirmed by independent third-party laboratory testing performed by Beacon Scientific Laboratories LLC, as documented in Lab Report No. BSL-2025-0412, dated March 15, 2025, a copy of which is enclosed herewith.

Apex's "clean" ingredients claim is therefore factually false as applied to the current DermaTrūe Pure product line and is designed to exploit outdated consumer perceptions of prior DermaTrūe formulations that are no longer on the market. The claim disparages DermaTrūe products by attributing to them ingredient characteristics they do not possess.

III. HARM TO THE INSURED

The false and misleading advertising campaign described above has caused, and continues to cause, substantial and quantifiable harm to Meridian across multiple dimensions. The categories of harm are summarized below.

A. Revenue and Profit Losses

The impact of Apex's "PuraClear Truth" campaign on DermaTrūe sales has been immediate, severe, and directly measurable. DermaTrūe revenue declined from $36.8 million in the third quarter of fiscal year 2024 (Q3 2024) to $29.4 million in the third quarter of fiscal year 2025 (Q3 2025) — a decline of $7.4 million, representing a year-over-year decrease of approximately 20.1%. This decline is temporally and causally correlated with the launch and escalation of the Apex campaign, and cannot be attributed to any other material change in market conditions, competitive dynamics, product quality, pricing, or distribution.

At DermaTrūe's historical gross margin of approximately 62.5%, the estimated lost gross profit attributable to the revenue decline in Q3 2025 alone is approximately $4.625 million. Annualized, assuming the campaign continues without correction or injunctive relief, the estimated annualized lost-profit figure is approximately $18.5 million. Meridian reserves the right to supplement these damage estimates as additional data becomes available, including through expert economic analysis in connection with the anticipated litigation.

B. Brand-Perception Damage

Beyond the direct financial losses, Apex's campaign has inflicted significant and measurable damage to the DermaTrūe brand's consumer perception and equity. A consumer-perception survey was commissioned by Meridian and conducted by Fisk Analytics Group LLC on August 22, 2025. The survey employed a nationally representative sample of 1,500 adults (ages 18 and older) and was conducted using methodologies consistent with accepted survey-research standards, with a margin of error of ±2.5 percentage points at a 95% confidence level.

The key findings of the Fisk Analytics survey were as follows:

• 34% of respondents who recalled having seen or heard the PuraClear advertisements believed that DermaTrūe products were "overpriced," compared to only 11% of respondents in a January 2025 baseline survey conducted by the same firm — an increase of 23 percentage points directly attributable to the false price-comparison advertising.

• 27% of respondents who recalled the PuraClear advertisements believed that DermaTrūe was "less effective than PuraClear," compared to only 8% in the January 2025 baseline survey — an increase of 19 percentage points directly attributable to the fabricated clinical-superiority claim.

These findings demonstrate that the false advertising has materially and adversely shifted consumer sentiment regarding the DermaTrūe brand in a manner that will require substantial corrective advertising expenditures to remediate, even after the false campaign is enjoined.

C. Retail Distribution Impact

The reverberating effects of Apex's campaign have now extended to Meridian's retail distribution relationships. On August 5, 2025, Kingsley Drug Stores LLC, a major national retail pharmacy and drugstore chain operating more than 2,400 retail locations across the United States, formally notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025. In its notification letter, a copy of which is enclosed, Kingsley Drug Stores cited "declining consumer demand" as the basis for the shelf-space reduction — demand that, as demonstrated above, was directly and artificially suppressed by Apex's false advertising. The estimated annual revenue impact to Meridian from the Kingsley Drug Stores shelf-space reduction alone is approximately $4.1 million.

Meridian is aware that similar shelf-space reviews may be underway at other major retail partners, and anticipates that additional distribution losses may materialize in the coming months absent injunctive relief. These anticipated losses will be documented and supplemented to Northbridge as they become known.

D. Apex's Unjust Enrichment

In addition to the direct losses suffered by Meridian, the false advertising campaign has conferred substantial unjust enrichment upon Apex. Based on available market data and competitive intelligence, Apex's estimated incremental PuraClear revenue during Q2 and Q3 2025 attributable to the false campaign is approximately $19.8 million. At an estimated PuraClear gross margin of 56.5%, the estimated disgorgeable profits flowing from Apex's false advertising are approximately $11.2 million. These figures will be subject to further refinement through discovery and expert analysis in the anticipated litigation.

IV. PRE-LITIGATION PROCEEDINGS AND ANTICIPATED LITIGATION

A. Cease-and-Desist Correspondence and Apex's Response

Upon first becoming aware of the "PuraClear Truth" campaign shortly after its June 2, 2025 launch, Meridian acted promptly to demand that Apex cease and desist from the false advertising. On June 18, 2025, Meridian's General Counsel, Derek Cho, sent a detailed cease-and-desist letter to Apex General Counsel Tanya Fischetti, demanding the immediate withdrawal of all "The PuraClear Truth" advertisements across all media channels and the issuance of a public retraction and correction. A copy of the cease-and-desist letter is enclosed.

On July 3, 2025, Apex responded through its outside counsel, Harrison Briggs of Caldwell, Briggs & Nolan LLP, categorically denying all of Meridian's allegations and asserting that all claims made in the "PuraClear Truth" campaign are truthful, substantiated, and protected speech. Apex refused to withdraw or modify any portion of the campaign. A copy of Apex's response letter is enclosed.

B. NAD Proceeding

In parallel with its direct engagement with Apex, Meridian sought industry self-regulatory review. On July 22, 2025, Meridian filed a formal complaint with the National Advertising Division ("NAD") of the Better Business Bureau, challenging the clinical-superiority, price-comparison, and "clean" ingredients claims (NAD Case Ref. No. NAD-2025-01847).

On August 15, 2025, following an expedited review, NAD issued a preliminary recommendation that Apex discontinue or materially modify the clinical-superiority and price-comparison claims pending the submission of adequate substantiation. A copy of the NAD preliminary recommendation is enclosed. Notably, Apex publicly stated through its counsel that it would appeal the NAD recommendation to the National Advertising Review Board and, in the interim, declined to modify or pause the campaign in any respect. The campaign remains active and ongoing as of the date of this letter.

C. Retention of Counsel and Anticipated Litigation

Given Apex's refusal to withdraw the false advertising through either direct negotiation or industry self-regulation, Meridian retained Calderwood & Harkness LLP on September 8, 2025, to initiate litigation to protect its rights. The Calderwood & Harkness engagement team for this matter consists of Linda Osei (responsible partner), Priya Anand (billing partner), Patrick Gallagher (lead associate), and Simone Laroche (working associate).

Meridian anticipates filing a verified complaint and an accompanying motion for a temporary restraining order and preliminary injunction in the United States District Court for the Southern District of New York on or about September 26, 2025. The anticipated case caption is:

Meridian Consumer Brands LLC v. Apex Naturals Inc., Case No. __ (S.D.N.Y.)

D. Anticipated Causes of Action

The verified complaint is expected to assert the following causes of action against Apex:

1. False Advertising under Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a) — based on the literally false clinical-superiority claim, the materially misleading price-comparison claim, and the factually false "clean" ingredients claim, all of which were made in interstate commerce in connection with the advertising and promotion of goods.

2. Deceptive Acts and Practices under New York General Business Law § 349 — based on Apex's consumer-oriented conduct that is misleading in a material way and has caused injury to Meridian.

3. False Advertising under New York General Business Law § 350 — based on Apex's advertising that is materially misleading to a reasonable consumer.

4. Common-Law Unfair Competition — based on Apex's bad-faith misrepresentations designed to divert trade and consumer goodwill from Meridian to Apex.

5. Tortious Interference with Business Relations — based on Apex's false advertising that directly and proximately caused Kingsley Drug Stores LLC and potentially other retailers to reduce or terminate their business relationships with Meridian.

E. Anticipated Relief

Meridian intends to seek the following relief in the anticipated litigation:

• Preliminary and permanent injunctive relief requiring Apex to immediately cease all dissemination of "The PuraClear Truth" campaign in its current form and to fund and publish corrective advertising sufficient to remedy the consumer confusion and brand damage caused by the false campaign.

• Compensatory damages for lost profits, with a preliminary estimate of approximately $18.5 million on an annualized basis, subject to refinement through expert economic analysis and discovery.

• Disgorgement of Apex's incremental PuraClear profits attributable to the false campaign, with a preliminary estimate of approximately $11.2 million.

• Treble damages under the Lanham Act in the event willfulness is established, which could increase the compensatory damages award up to approximately $55.5 million (i.e., $18.5 million × 3).

• Reasonable attorneys' fees and costs as provided under the Lanham Act and applicable state statutes.

The aggregate potential exposure in this matter, inclusive of treble damages, disgorgement, corrective advertising costs, and attorneys' fees, is substantial and well within the scope of the Policy's per-occurrence and aggregate limits.

V. APPLICABILITY OF THE POLICY / BASIS FOR COVERAGE

Meridian submits that the false advertising campaign launched and maintained by Apex constitutes an "advertising injury" as that term is defined under the commercial general liability / advertising-injury endorsement of Policy No. NM-GL-2024-88173 issued by Northbridge to Meridian. Specifically, the Policy provides coverage for injury arising out of one or more "advertising injury" offenses committed in the course of advertising the insured's or another party's goods, products, or services.

The occurrence giving rise to this claim — namely, the launch and continuing nationwide dissemination of "The PuraClear Truth" false advertising campaign — began on June 2, 2025 and remains ongoing as of the date of this letter. The occurrence therefore falls squarely within the Policy period of January 1, 2025 through January 1, 2026.

The harm suffered by Meridian includes, without limitation, injury arising out of the oral and written publication, in any manner, of material that disparages Meridian's goods, products, and services. Apex's advertisements contain statements that are literally false and/or materially misleading with respect to the efficacy, price, and ingredient composition of Meridian's DermaTrūe products. These statements directly disparage DermaTrūe products by conveying false messages that they are less effective, more expensive, and less "clean" than competing products. Additionally, Apex's campaign constitutes misappropriation of Meridian's advertising ideas and style of doing business by exploiting and distorting the DermaTrūe brand name and product imagery in a manner calculated to divert consumer demand.

Meridian has suffered quantifiable economic losses — including lost revenue, lost profits, brand-equity damage, retail distribution losses, and ongoing reputational harm — directly and proximately caused by Apex's false and disparaging advertising. These losses are the type of advertising-injury damages for which the Policy was designed to provide coverage.

Given the magnitude of the damages at issue — including preliminary lost-profit estimates of $18.5 million annualized, potential disgorgement of $11.2 million, and potential treble damages of up to $55.5 million — the Policy's per-occurrence limit of $10,000,000 and aggregate limit of $25,000,000 are potentially implicated in their entirety.

VI. REQUESTS

In light of the foregoing, Meridian respectfully requests that Northbridge Mutual Insurance Company take the following actions promptly:

1. Acknowledge receipt of this coverage notification in writing;

2. Assign a claim number to this matter and communicate such number to undersigned counsel;

3. Confirm that the advertising-injury endorsement under Policy No. NM-GL-2024-88173 provides coverage for the losses, damages, and defense costs described herein;

4. Identify the Northbridge claims adjuster and/or coverage counsel assigned to this matter, and provide direct contact information for such individual(s); and

5. Respond in writing within the timeframe required by the Policy and applicable law, including but not limited to the requirements of applicable state insurance regulations governing timely acknowledgment of and response to coverage notifications.

VII. RESERVATION OF RIGHTS

By providing this notice, Meridian does not waive, and expressly does not intend to waive, any rights, claims, or defenses under the Policy, at law, or in equity. This letter is not intended to be, and shall not be construed as, a complete or exhaustive description of all facts, circumstances, damages, or legal theories that may be relevant to Meridian's claim for coverage.

Meridian expressly reserves all rights to seek coverage for any and all damages, losses, costs, expenses, defense costs, indemnity obligations, and other liabilities arising from or related to the Apex false-advertising dispute described herein, whether currently known or subsequently discovered, and whether arising under the advertising-injury endorsement, the general liability coverage, or any other provision of the Policy.

Meridian further reserves the right to supplement, amend, or update this notice as additional information, facts, damages, or claims become available, including but not limited to information obtained through discovery in the anticipated litigation, expert analyses, supplemental damage calculations, and additional pre-litigation or litigation developments.

Nothing in this letter shall constitute an admission or concession regarding any issue of fact or law, nor shall it be construed as a limitation on the scope of coverage to which Meridian may be entitled under the Policy.

VIII. CONTACT INFORMATION AND DOCUMENT PRESERVATION

All correspondence, communications, and notices from Northbridge regarding this claim should be directed to:

Linda Osei, Partner Calderwood & Harkness LLP 600 Lexington Avenue, 30th Floor New York, NY 10022 Telephone: (212) 554-8024

Email: losei@calderwoodharkness.com

with a copy to:

Derek Cho, General Counsel Meridian Consumer Brands LLC 410 West 34th Street, 18th Floor New York, NY 10001 Telephone: (212) 390-4500

Email: dcho@meridiancb.com

Additionally, Meridian hereby requests that Northbridge immediately undertake to preserve all documents, communications, electronically stored information, underwriting files, claims files, and any other records related to Policy No. NM-GL-2024-88173 and any prior communications with or regarding Meridian Consumer Brands LLC. This preservation request applies to all such materials in the possession, custody, or control of Northbridge, its employees, agents, adjusters, outside counsel, reinsurers, and any other third parties acting on Northbridge's behalf.

CLOSING

We appreciate your prompt attention to this matter. The ongoing nature of Apex's false advertising campaign and the substantial and continuing harm being inflicted upon Meridian make the timely processing of this coverage notification a matter of significant urgency.

Should Northbridge require any additional information, documentation, or clarification in connection with this coverage notification, please do not hesitate to contact the undersigned directly. We are prepared to make ourselves and Meridian's representatives available at Northbridge's convenience to discuss any aspect of this claim.

Meridian looks forward to Northbridge's timely written response acknowledging this notification and confirming coverage under the Policy.

Thank you for your courtesy and cooperation.

Respectfully submitted,

CALDERWOOD & HARKNESS LLP

By: ________

Linda Osei, Partner 600 Lexington Avenue, 30th Floor New York, NY 10022 Telephone: (212) 554-8024

Email: losei@calderwoodharkness.com

cc: Derek Cho, General Counsel, Meridian Consumer Brands LLC Priya Anand, Partner, Calderwood & Harkness LLP

Enclosures:

1. Copy of Policy No. NM-GL-2024-88173 — Declarations Page

2. Cease-and-Desist Letter dated June 18, 2025 (D. Cho to T. Fischetti)

3. Apex Response Letter dated July 3, 2025 (H. Briggs / Caldwell, Briggs & Nolan LLP)

4. NAD Preliminary Recommendation dated August 15, 2025 (Case Ref. No. NAD-2025-01847)

5. Beacon Scientific Laboratories LLC — Lab Report No. BSL-2025-0412 (dated March 15, 2025)

6. Exemplar Screenshots and Copies of "The PuraClear Truth" Campaign Materials

7. Kingsley Drug Stores LLC — Notification Letter dated August 5, 2025

CALDERWOOD & HARKNESS LLP Attorneys at Law 600 Lexington Avenue, 30th Floor New York, NY 10022 Telephone: (212) 554-8000 Facsimile: (212) 554-8001 www.calderwoodharkness.com
September 11, 2025
VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED AND ELECTRONIC MAIL (claims@northbridgemutual.com)
Northbridge Mutual Insurance Company Claims Department 1200 Post Road, Suite 500 Hartford, CT 06103
Re: Coverage Notification — Advertising-Injury Claim Policy No.: NM-GL-2024-88173 Named Insured: Meridian Consumer Brands LLC Policy Period: January 1, 2025 – January 1, 2026 Calderwood & Harkness LLP Matter No.: 1011-00004
Dear Sir or Madam:
This firm, Calderwood & Harkness LLP, represents Meridian Consumer Brands LLC ("Meridian" or "MCB"), a Delaware limited liability company with its principal place of business at 410 West 34th Street, 18th Floor, New York, NY 10001. We write on behalf of Meridian to provide timely notice of a claim and/or potential claim under the above-referenced commercial general liability / advertising-injury insurance policy issued by Northbridge Mutual Insurance Company ("Northbridge") to Meridian. Meridian is the named insured under Policy No. NM-GL-2024-88173, which provides, among other coverages, a per-occurrence limit of $10,000,000 and an aggregate limit of $25,000,000. This letter constitutes formal notice of an occurrence and/or claim arising from a false and disparaging advertising campaign directed at Meridian by a competitor, Apex Naturals Inc. ("Apex"). Meridian submits this notice in accordance with the notice provisions of the Policy and applicable law, and respectfully requests that Northbridge acknowledge coverage and assign a claims handler to this matter without delay.
The facts and circumstances giving rise to this notification are set forth in detail below.
I. BACKGROUND ON THE INSURED
Meridian Consumer Brands LLC is a premium consumer products company specializing in the development, manufacture, marketing, and sale of skincare, personal-care, and over-the-counter dermatological products distributed through major retail, e-commerce, and direct-to-consumer channels throughout the United States and select international markets. Meridian was acquired in 2019 by Brindoval Capital Partners Fund IV LP, a private equity fund, and has since undergone significant brand investment, product reformulation, and distribution expansion.
Meridian's portfolio of brands includes three principal product lines: DermaTrūe, a clinically tested acne and blemish treatment line; Velara, a premium anti-aging skincare collection; and SkinSense, a dermatologist-recommended sensitive-skin care line. Of these, the DermaTrūe line is Meridian's flagship brand and the primary subject of the advertising injury described herein.
For fiscal year 2024, Meridian reported total consolidated revenue of approximately $487.6 million. The DermaTrūe product line alone generated approximately $138.2 million in revenue, representing approximately 28.3% of Meridian's total revenue, making it the single most significant revenue contributor in Meridian's brand portfolio. DermaTrūe products are sold in over 40,000 retail locations nationwide, including major drugstore chains, mass-market retailers, and specialty beauty retailers.
Meridian's Chief Executive Officer is Nathan Hartwell, and its General Counsel is Derek Cho. Meridian's outside auditors are Ashford & Kline LLP, with engagement partner Roger Brennan overseeing the audit relationship. These individuals and entities are referenced herein to provide Northbridge with a complete understanding of the insured's organizational profile and the financial significance of the claims at issue.
II. DESCRIPTION OF THE OCCURRENCE / ADVERTISING INJURY
A. The Adverse Party
The advertising injury at issue was caused by Apex Naturals Inc. ("Apex"), a Delaware corporation headquartered at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex is a mass-market and "clean-beauty" skincare company that competes directly with Meridian in the acne-treatment and general skincare product categories. For fiscal year 2024, Apex's estimated revenue was approximately $312.4 million. Apex's Chief Executive Officer and Founder is Marcus Devlin, and its General Counsel is Tanya Fischetti. In connection with the matters described herein, Apex is represented by outside counsel Harrison Briggs, lead partner at Caldwell, Briggs & Nolan LLP, 200 Park Avenue, 42nd Floor, New York, NY 10166.
B. The False Advertising Campaign
On or about June 2, 2025, Apex launched a nationwide comparative advertising campaign titled "The PuraClear Truth" (internally code-named "Project Clarity") promoting its PuraClear acne-treatment product line in direct and explicit comparison with Meridian's flagship DermaTrūe product family. The campaign was conceived, developed, and produced by Brightline Creative Partners LLC, a creative advertising agency headquartered at 55 Washington Street, Suite 900, Brooklyn, New York 11201, under the direction of its Chief Creative Officer, Owen Prescott.
The "PuraClear Truth" campaign was disseminated across an extensive array of media channels, including but not limited to: (i) national television advertising in the form of 30-second and 60-second commercial spots aired during primetime, daytime, and cable programming on major broadcast and cable networks; (ii) digital video advertising distributed through Crowne Albany Partners LLC pre-roll and mid-roll placements, Dunmore & Co. sponsored content, and Northpoint Services Inc. Reels; (iii) in-store point-of-sale displays, shelf talkers, and endcap signage deployed at major national drugstore chains; (iv) print advertisements placed in widely circulated consumer magazines; and (v) a dedicated campaign webpage hosted at www.apexnaturals.com/puraclear-truth, which aggregated campaign materials, purported clinical data, and consumer testimonials.
Based on information and belief, Apex's estimated total expenditure on "The PuraClear Truth" campaign from its June 2, 2025 launch through August 2025 was approximately $23.0 million, comprised of approximately $14.3 million in national television media buys and approximately $8.7 million in digital and social media expenditures. The sheer scale of the campaign spend underscores the breadth of dissemination and the magnitude of the resulting harm to Meridian.
C. The Three Categories of False and Misleading Claims
Meridian's investigation, conducted in consultation with outside scientific consultants, independent laboratories, and marketing analysts, has identified three distinct categories of materially false and/or misleading claims made by Apex in the "PuraClear Truth" campaign. Each category is described in detail below.
(i) Fabricated Clinical Superiority Claim. The central and most prominent claim in Apex's advertising campaign is a purported clinical-superiority claim. Specifically, Apex's television, digital, print, and point-of-sale advertisements prominently state:
"In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment."
This claim is attributed in the advertisements to a citation reading "Guerrero et al., 2024, Independent Dermatological Review." The citation is formatted in a manner designed to convey the impression that the referenced study was published in a peer-reviewed scientific journal.
Meridian's investigation has revealed that no study authored by "Guerrero et al." was published in 2024, or at any other time, in any peer-reviewed dermatological, medical, or scientific journal. Furthermore, no journal titled "Independent Dermatological Review" exists in any recognized index of scientific or medical publications, including PubMed, MEDLINE, the Cochrane Library, or the Directory of Open Access Journals.
Upon further investigation, Meridian has determined that the underlying data upon which Apex's clinical-superiority claim appears to rest derives from a non-blinded, internally conducted pilot study involving only twenty-two (22) participants, with no placebo or active control group, no randomization protocol, and no independent oversight or peer review. This pilot study was conducted by Apex's own internal product-development team and was never submitted for peer review or publication. The fabrication of a fictitious journal citation and the representation of a deeply flawed internal pilot study as a "controlled clinical study" renders the clinical-superiority claim literally false within the meaning of Section 43(a) of the Lanham Act and applicable state consumer-protection statutes.
(ii) Misleading Price-Comparison Claim. Apex's campaign also prominently features a price-comparison claim designed to convey the impression that PuraClear products are dramatically less expensive than comparable DermaTrūe products. Specifically, the advertisements state:
"PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit."
This comparison is materially misleading because it compares products that are not, in fact, comparable in any meaningful sense. The PuraClear product referenced in the comparison is a single 1.0 oz. tube of PuraClear Spot Treatment, priced at $12.99, which equates to a per-ounce price of $12.99 per ounce. The DermaTrūe product referenced at the $28.99 price point is the DermaTrūe Complete Acne System, which is a three-piece regimen kit containing a 2.0 oz. cleanser, a 1.5 oz. treatment gel, and a 1.7 oz. moisturizer — a total of 5.2 oz. of product — priced at $28.99, which equates to a per-ounce price of approximately $5.57 per ounce.
When the products are compared on a per-ounce basis — the standard and most appropriate metric for evaluating product value in the consumer skincare category — PuraClear's per-ounce price of $12.99 is, in fact, more than double the DermaTrūe per-ounce price of $5.57. The advertisement's claim that PuraClear is available "at half the price" of a "comparable" DermaTrūe product is therefore not merely misleading but is the precise inverse of reality. This claim is materially misleading and likely to deceive a substantial segment of the relevant consuming public.
(iii) False "Clean" Ingredients Claim. The third category of false claims concerns the purity and ingredient composition of DermaTrūe products. Apex's advertisements state:
"Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances."
This claim is designed to convey the false impression that DermaTrūe products contain parabens, sulfates, and/or synthetic fragrances, and that PuraClear is superior by virtue of their absence. However, in 2024, Meridian completed a comprehensive reformulation of its entire DermaTrūe product line, relaunching it under the designation "DermaTrūe Pure." The reformulated DermaTrūe Pure products are, in fact, also free of parabens, sulfates, and synthetic fragrances. This has been confirmed by independent third-party laboratory testing performed by Beacon Scientific Laboratories LLC, as documented in Lab Report No. BSL-2025-0412, dated March 15, 2025, a copy of which is enclosed herewith.
Apex's "clean" ingredients claim is therefore factually false as applied to the current DermaTrūe Pure product line and is designed to exploit outdated consumer perceptions of prior DermaTrūe formulations that are no longer on the market. The claim disparages DermaTrūe products by attributing to them ingredient characteristics they do not possess.
III. HARM TO THE INSURED
The false and misleading advertising campaign described above has caused, and continues to cause, substantial and quantifiable harm to Meridian across multiple dimensions. The categories of harm are summarized below.
A. Revenue and Profit Losses
The impact of Apex's "PuraClear Truth" campaign on DermaTrūe sales has been immediate, severe, and directly measurable. DermaTrūe revenue declined from $36.8 million in the third quarter of fiscal year 2024 (Q3 2024) to $29.4 million in the third quarter of fiscal year 2025 (Q3 2025) — a decline of $7.4 million, representing a year-over-year decrease of approximately 20.1%. This decline is temporally and causally correlated with the launch and escalation of the Apex campaign, and cannot be attributed to any other material change in market conditions, competitive dynamics, product quality, pricing, or distribution.
At DermaTrūe's historical gross margin of approximately 62.5%, the estimated lost gross profit attributable to the revenue decline in Q3 2025 alone is approximately $4.625 million. Annualized, assuming the campaign continues without correction or injunctive relief, the estimated annualized lost-profit figure is approximately $18.5 million. Meridian reserves the right to supplement these damage estimates as additional data becomes available, including through expert economic analysis in connection with the anticipated litigation.
B. Brand-Perception Damage
Beyond the direct financial losses, Apex's campaign has inflicted significant and measurable damage to the DermaTrūe brand's consumer perception and equity. A consumer-perception survey was commissioned by Meridian and conducted by Fisk Analytics Group LLC on August 22, 2025. The survey employed a nationally representative sample of 1,500 adults (ages 18 and older) and was conducted using methodologies consistent with accepted survey-research standards, with a margin of error of ±2.5 percentage points at a 95% confidence level.
The key findings of the Fisk Analytics survey were as follows:
• 34% of respondents who recalled having seen or heard the PuraClear advertisements believed that DermaTrūe products were "overpriced," compared to only 11% of respondents in a January 2025 baseline survey conducted by the same firm — an increase of 23 percentage points directly attributable to the false price-comparison advertising.
• 27% of respondents who recalled the PuraClear advertisements believed that DermaTrūe was "less effective than PuraClear," compared to only 8% in the January 2025 baseline survey — an increase of 19 percentage points directly attributable to the fabricated clinical-superiority claim.
These findings demonstrate that the false advertising has materially and adversely shifted consumer sentiment regarding the DermaTrūe brand in a manner that will require substantial corrective advertising expenditures to remediate, even after the false campaign is enjoined.
C. Retail Distribution Impact
The reverberating effects of Apex's campaign have now extended to Meridian's retail distribution relationships. On August 5, 2025, Kingsley Drug Stores LLC, a major national retail pharmacy and drugstore chain operating more than 2,400 retail locations across the United States, formally notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025. In its notification letter, a copy of which is enclosed, Kingsley Drug Stores cited "declining consumer demand" as the basis for the shelf-space reduction — demand that, as demonstrated above, was directly and artificially suppressed by Apex's false advertising. The estimated annual revenue impact to Meridian from the Kingsley Drug Stores shelf-space reduction alone is approximately $4.1 million.
Meridian is aware that similar shelf-space reviews may be underway at other major retail partners, and anticipates that additional distribution losses may materialize in the coming months absent injunctive relief. These anticipated losses will be documented and supplemented to Northbridge as they become known.
D. Apex's Unjust Enrichment
In addition to the direct losses suffered by Meridian, the false advertising campaign has conferred substantial unjust enrichment upon Apex. Based on available market data and competitive intelligence, Apex's estimated incremental PuraClear revenue during Q2 and Q3 2025 attributable to the false campaign is approximately $19.8 million. At an estimated PuraClear gross margin of 56.5%, the estimated disgorgeable profits flowing from Apex's false advertising are approximately $11.2 million. These figures will be subject to further refinement through discovery and expert analysis in the anticipated litigation.
IV. PRE-LITIGATION PROCEEDINGS AND ANTICIPATED LITIGATION
A. Cease-and-Desist Correspondence and Apex's Response
Upon first becoming aware of the "PuraClear Truth" campaign shortly after its June 2, 2025 launch, Meridian acted promptly to demand that Apex cease and desist from the false advertising. On June 18, 2025, Meridian's General Counsel, Derek Cho, sent a detailed cease-and-desist letter to Apex General Counsel Tanya Fischetti, demanding the immediate withdrawal of all "The PuraClear Truth" advertisements across all media channels and the issuance of a public retraction and correction. A copy of the cease-and-desist letter is enclosed.
On July 3, 2025, Apex responded through its outside counsel, Harrison Briggs of Caldwell, Briggs & Nolan LLP, categorically denying all of Meridian's allegations and asserting that all claims made in the "PuraClear Truth" campaign are truthful, substantiated, and protected speech. Apex refused to withdraw or modify any portion of the campaign. A copy of Apex's response letter is enclosed.
B. NAD Proceeding
In parallel with its direct engagement with Apex, Meridian sought industry self-regulatory review. On July 22, 2025, Meridian filed a formal complaint with the National Advertising Division ("NAD") of the Better Business Bureau, challenging the clinical-superiority, price-comparison, and "clean" ingredients claims (NAD Case Ref. No. NAD-2025-01847).
On August 15, 2025, following an expedited review, NAD issued a preliminary recommendation that Apex discontinue or materially modify the clinical-superiority and price-comparison claims pending the submission of adequate substantiation. A copy of the NAD preliminary recommendation is enclosed. Notably, Apex publicly stated through its counsel that it would appeal the NAD recommendation to the National Advertising Review Board and, in the interim, declined to modify or pause the campaign in any respect. The campaign remains active and ongoing as of the date of this letter.
C. Retention of Counsel and Anticipated Litigation
Given Apex's refusal to withdraw the false advertising through either direct negotiation or industry self-regulation, Meridian retained Calderwood & Harkness LLP on September 8, 2025, to initiate litigation to protect its rights. The Calderwood & Harkness engagement team for this matter consists of Linda Osei (responsible partner), Priya Anand (billing partner), Patrick Gallagher (lead associate), and Simone Laroche (working associate).
Meridian anticipates filing a verified complaint and an accompanying motion for a temporary restraining order and preliminary injunction in the United States District Court for the Southern District of New York on or about September 26, 2025. The anticipated case caption is:
Meridian Consumer Brands LLC v. Apex Naturals Inc., Case No. __ (S.D.N.Y.)
D. Anticipated Causes of Action
The verified complaint is expected to assert the following causes of action against Apex:
1. False Advertising under Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a) — based on the literally false clinical-superiority claim, the materially misleading price-comparison claim, and the factually false "clean" ingredients claim, all of which were made in interstate commerce in connection with the advertising and promotion of goods.
2. Deceptive Acts and Practices under New York General Business Law § 349 — based on Apex's consumer-oriented conduct that is misleading in a material way and has caused injury to Meridian.
3. False Advertising under New York General Business Law § 350 — based on Apex's advertising that is materially misleading to a reasonable consumer.
4. Common-Law Unfair Competition — based on Apex's bad-faith misrepresentations designed to divert trade and consumer goodwill from Meridian to Apex.
5. Tortious Interference with Business Relations — based on Apex's false advertising that directly and proximately caused Kingsley Drug Stores LLC and potentially other retailers to reduce or terminate their business relationships with Meridian.
E. Anticipated Relief
Meridian intends to seek the following relief in the anticipated litigation:
• Preliminary and permanent injunctive relief requiring Apex to immediately cease all dissemination of "The PuraClear Truth" campaign in its current form and to fund and publish corrective advertising sufficient to remedy the consumer confusion and brand damage caused by the false campaign.
• Compensatory damages for lost profits, with a preliminary estimate of approximately $18.5 million on an annualized basis, subject to refinement through expert economic analysis and discovery.
• Disgorgement of Apex's incremental PuraClear profits attributable to the false campaign, with a preliminary estimate of approximately $11.2 million.
• Treble damages under the Lanham Act in the event willfulness is established, which could increase the compensatory damages award up to approximately $55.5 million (i.e., $18.5 million × 3).
• Reasonable attorneys' fees and costs as provided under the Lanham Act and applicable state statutes.
The aggregate potential exposure in this matter, inclusive of treble damages, disgorgement, corrective advertising costs, and attorneys' fees, is substantial and well within the scope of the Policy's per-occurrence and aggregate limits.
V. APPLICABILITY OF THE POLICY / BASIS FOR COVERAGE
Meridian submits that the false advertising campaign launched and maintained by Apex constitutes an "advertising injury" as that term is defined under the commercial general liability / advertising-injury endorsement of Policy No. NM-GL-2024-88173 issued by Northbridge to Meridian. Specifically, the Policy provides coverage for injury arising out of one or more "advertising injury" offenses committed in the course of advertising the insured's or another party's goods, products, or services.
The occurrence giving rise to this claim — namely, the launch and continuing nationwide dissemination of "The PuraClear Truth" false advertising campaign — began on June 2, 2025 and remains ongoing as of the date of this letter. The occurrence therefore falls squarely within the Policy period of January 1, 2025 through January 1, 2026.
The harm suffered by Meridian includes, without limitation, injury arising out of the oral and written publication, in any manner, of material that disparages Meridian's goods, products, and services. Apex's advertisements contain statements that are literally false and/or materially misleading with respect to the efficacy, price, and ingredient composition of Meridian's DermaTrūe products. These statements directly disparage DermaTrūe products by conveying false messages that they are less effective, more expensive, and less "clean" than competing products. Additionally, Apex's campaign constitutes misappropriation of Meridian's advertising ideas and style of doing business by exploiting and distorting the DermaTrūe brand name and product imagery in a manner calculated to divert consumer demand.
Meridian has suffered quantifiable economic losses — including lost revenue, lost profits, brand-equity damage, retail distribution losses, and ongoing reputational harm — directly and proximately caused by Apex's false and disparaging advertising. These losses are the type of advertising-injury damages for which the Policy was designed to provide coverage.
Given the magnitude of the damages at issue — including preliminary lost-profit estimates of $18.5 million annualized, potential disgorgement of $11.2 million, and potential treble damages of up to $55.5 million — the Policy's per-occurrence limit of $10,000,000 and aggregate limit of $25,000,000 are potentially implicated in their entirety.
VI. REQUESTS
In light of the foregoing, Meridian respectfully requests that Northbridge Mutual Insurance Company take the following actions promptly:
1. Acknowledge receipt of this coverage notification in writing;
2. Assign a claim number to this matter and communicate such number to undersigned counsel;
3. Confirm that the advertising-injury endorsement under Policy No. NM-GL-2024-88173 provides coverage for the losses, damages, and defense costs described herein;
4. Identify the Northbridge claims adjuster and/or coverage counsel assigned to this matter, and provide direct contact information for such individual(s); and
5. Respond in writing within the timeframe required by the Policy and applicable law, including but not limited to the requirements of applicable state insurance regulations governing timely acknowledgment of and response to coverage notifications.
VII. RESERVATION OF RIGHTS
By providing this notice, Meridian does not waive, and expressly does not intend to waive, any rights, claims, or defenses under the Policy, at law, or in equity. This letter is not intended to be, and shall not be construed as, a complete or exhaustive description of all facts, circumstances, damages, or legal theories that may be relevant to Meridian's claim for coverage.
Meridian expressly reserves all rights to seek coverage for any and all damages, losses, costs, expenses, defense costs, indemnity obligations, and other liabilities arising from or related to the Apex false-advertising dispute described herein, whether currently known or subsequently discovered, and whether arising under the advertising-injury endorsement, the general liability coverage, or any other provision of the Policy.
Meridian further reserves the right to supplement, amend, or update this notice as additional information, facts, damages, or claims become available, including but not limited to information obtained through discovery in the anticipated litigation, expert analyses, supplemental damage calculations, and additional pre-litigation or litigation developments.
Nothing in this letter shall constitute an admission or concession regarding any issue of fact or law, nor shall it be construed as a limitation on the scope of coverage to which Meridian may be entitled under the Policy.
VIII. CONTACT INFORMATION AND DOCUMENT PRESERVATION
All correspondence, communications, and notices from Northbridge regarding this claim should be directed to:
Linda Osei, Partner Calderwood & Harkness LLP 600 Lexington Avenue, 30th Floor New York, NY 10022 Telephone: (212) 554-8024
Email: losei@calderwoodharkness.com
with a copy to:
Derek Cho, General Counsel Meridian Consumer Brands LLC 410 West 34th Street, 18th Floor New York, NY 10001 Telephone: (212) 390-4500
Email: dcho@meridiancb.com
Additionally, Meridian hereby requests that Northbridge immediately undertake to preserve all documents, communications, electronically stored information, underwriting files, claims files, and any other records related to Policy No. NM-GL-2024-88173 and any prior communications with or regarding Meridian Consumer Brands LLC. This preservation request applies to all such materials in the possession, custody, or control of Northbridge, its employees, agents, adjusters, outside counsel, reinsurers, and any other third parties acting on Northbridge's behalf.
CLOSING
We appreciate your prompt attention to this matter. The ongoing nature of Apex's false advertising campaign and the substantial and continuing harm being inflicted upon Meridian make the timely processing of this coverage notification a matter of significant urgency.
Should Northbridge require any additional information, documentation, or clarification in connection with this coverage notification, please do not hesitate to contact the undersigned directly. We are prepared to make ourselves and Meridian's representatives available at Northbridge's convenience to discuss any aspect of this claim.
Meridian looks forward to Northbridge's timely written response acknowledging this notification and confirming coverage under the Policy.
Thank you for your courtesy and cooperation.
Respectfully submitted,
CALDERWOOD & HARKNESS LLP
By: ________
Linda Osei, Partner 600 Lexington Avenue, 30th Floor New York, NY 10022 Telephone: (212) 554-8024
Email: losei@calderwoodharkness.com
cc: Derek Cho, General Counsel, Meridian Consumer Brands LLC Priya Anand, Partner, Calderwood & Harkness LLP
Enclosures:
1. Copy of Policy No. NM-GL-2024-88173 — Declarations Page
2. Cease-and-Desist Letter dated June 18, 2025 (D. Cho to T. Fischetti)
3. Apex Response Letter dated July 3, 2025 (H. Briggs / Caldwell, Briggs & Nolan LLP)
4. NAD Preliminary Recommendation dated August 15, 2025 (Case Ref. No. NAD-2025-01847)
5. Beacon Scientific Laboratories LLC — Lab Report No. BSL-2025-0412 (dated March 15, 2025)
6. Exemplar Screenshots and Copies of "The PuraClear Truth" Campaign Materials
7. Kingsley Drug Stores LLC — Notification Letter dated August 5, 2025